The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Offer details
Expected size of offer (M): 40m
Expected first date of trading: 27/03/2014
Market: AIM
Location of address at which admission document will be available: Copies of the Admission Document, which will contain full details about the applicant and the admission of its securities, will be available on the Group's website (www.horizondiscovery.com).
Date at which admission document will be available: -

Advisors
Sponsor: -
Nominated Advisor (AIM Companies): Panmure Gordon (UK) Limited
Nominated Broker (AIM Companies): Panmure Gordon (UK) Limited
Financial PR Advisors: -

Company details
Name Role
Dr Ian David Gilham Non-executive Chairman
Dr Darrin Matthew Disley Chief Executive Officer
Richard John Vellacott Chief Financial Officer
Dr Jonathan Simon Milner Non-executive Director
Dr Vishal Kumar Gulati Non-executive Director

Facts and Figures
Fiscal year end: 31 December
Incorporated in: England and Wales
Website URL: www.horizondiscovery.com
space
Description of business:
Horizon is a revenue-generating life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines. The Group, which is Cambridge (UK) based, has a diverse and international customer base approaching 800 organisations, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research ce...

Person(s) interested:
Significant shareholders of existing share capital pre-admission*: Dr Jonathan Milner 21.7% DFJ Esprit** *** 16.9% Dr Chris Torrance 9.4% MVM Life Science Partners**** 8.2% Roche Finance Ltd 6.0% Execute Technologies Inc 5.6% Dr Alberto Bardelli 4.8% The Chancellor, Masters and Scholars of the University of Cambridge 3.9% Genentech Inc 3.6% Peter Collins 3.1% Significant shareholders after admission: Jonathan Milner 14.5% Legal & General Investment Management Ltd 7.5% DFJ Esprit** *** 6.1% Hargreave Hale 4.2% Henderson Global Investors 4.2% Henderson Volantis 4.2% Invesco Asset Management Limited 3.9% Execute Technologies Inc 3.7% Odey Asset Management LLP 3.3% * This assumes that the consolidation (as part of the Company's corporate restructuring to list on AIM) has taken place pre-Admission ** Dr Vishal Gulati, Non-executive Director, acts as an Investment Director for DFJ Esprit *** Total numbers are the aggregate amounts held by different DFJ Esprit entities **** Total numbers are the aggregate amounts held by different MVM Life Science Partners entities


Horizon Discovery Group plc

Related links

Further informations about 7 and 7/30 days issues can be find by clicking on one of the options below:

Issues last 7 days

Last issues 7/30 days

Back to New and recent issues - Home



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds